IL23A and inflammatory bowel disease: Unlike monoclonal antibodies used in IBD treatment, which selectively target a single cytokine (e.g., TNFα, and IL-23), JAK inhibitors (JAKi) simultaneously modulate multiple inflammatory pathways.